Learn more about this research?
- You have a light colored skin
- You are a non-smoker
- Your body must be at least 60 kg and your Body Mass Index (BMI) is between 20.0 and 30.0 kg/m2. The BMI shows the relation between body weight in kilograms and heigth in meters.
- You have never been addicted to recreational drugs
- Women are only allowed to participate in this study if they are using sufficient contraception or have been
postmenopausal for at least two years or have been surgically sterilized
- To determine if you are eligible for participation in this study, you will undergo a medical screening.
You will receive a gross compensation of € 2.072,- for participation in one of the groups.
Travelling expenses will be reimbursed based on the distance traveled (€ 0,19 net per kilometer) with a minimum of € 12,- and a maximum of € 160,- (840 kilometers) per return, regardless of the mode of transportation.
Period of stay and research
The study consists of 1 period during which you will stay in our research facility in Groningen (location Martini) for
13 days (12 nights).
Please note: You have to be available for all dates for the group to be able to participate in this study. These are the currently planned dates; however, these may be subject to change.
Narcolepsy is a sleeping disorder that involves excessive daytime sleepiness and, in some patients, a sudden
loss of muscle tone usually triggered by strong emotion (cataplexy).
Information sheet PRA-173371
Type of study
The purpose of the study is to investigate how quickly and to what extent the experimental drug is absorbed and eliminated from the body. The comparison is called relative bioavailability. The safety and to what extent the experimental drug is tolerated will also be investigated. The experimental drug is not registered as a drug, and will be given to humans for the first time. The study will only take place after it has been approved by the Independent Ethics Committee.
Setup and duration of the study
The actual study will consist of 1 period during which you will stay in our clinical research facility in Groningen (location Martini) for 13 days (12 nights). Before the start of the study you will visit the medical screening center. During this study you will receive 5 treatments that consist of the new drug administered orally as a mixture of small pellets approximately 1mm diameter, that contain the same active ingredient and 1 treatment with an existing compound as an oral solution every other day for 12 days.
4 of the investigated compounds are developed such that the active compound is slowly distributed over the body after intake and 1 solution is developed such that the active compound is immediately absorbed by the body after intake. Each volunteer will receive each treatment once, the order in which the treatments will be given will be determined by chance. Blood samples will be taken regularly. Also your alertness during the first 4 hours after the administration will be checked.
Risks and medical supervision
The experimental drug is being evaluated for the treatment of narcolepsy. Narcolepsy is a sleeping disorder that involves excessive daytime sleepiness and, in some patients, a sudden loss of muscle tone usually triggered by strong emotion (cataplexy). One of the current medications for excessive daytime sleepiness and cataplexy in narcolepsy is an oral solution (registered drug) that contains a high amount of sodium at the highest approved dose. The active substance of the registered drug has depressant or sedating effects in people.
All drugs have the potential to cause adverse events. The extent to which this occurs differs by investigation. In clinical studies with the registered compound in subjects with narcolepsy, the most common adverse effects were nausea, dizziness, vomiting, somnolence (sleepiness), enuresis (inability to control urination especially during sleep), and tremor (muscle twitching). Overall, the adverse effects observed in clinical studies with healthy volunteers are similar to those seen in patients. You will be under strict medical supervision during the study. Due to possible extended release effect of the experimental drug, we strongly advise you travel home by public transport or to have someone pick you up after your discharge from the clinical research facility, since you may not be fit enough to drive a car.
Conditions for participation
You are a healthy male or female between 18 and 45 years old. You can only take part in the study if you do not smoke, never have been addicted to recreational drugs and if you are able to fast for at least 10 hours before eating a standardized high-fat, high-calorie breakfast and 6 hours more after taking the study drug. Participants must use adequate measures to prevent any pregnancy during the entire study and for 3 months (90 days) after completing the study. Women must use medically acceptable methods of contraception (birth control), be post-menopausal for at least two years or be surgically sterile. Males may not donate sperm for 3 months (90 day) after completing the study. Since the metabolism of the drug in the body can vary based on ethnicity, only Caucasian volunteers who are not Hispanic or Latino can participate.
The study will be executed under standardized conditions. Use of your own medication, alcohol, regular coffee and tea, cola, power drinks, chocolate (including products made of chocolate), grapefruit (juice) and tobacco products during the study is not allowed. Also before the study there will be restrictions for these products. Use of decaffeinated coffee and (herbal) teas without caffeine is allowed. Before you are allowed to take part in the study, you will be medically screened; this screening will take place within three weeks before the start of the study.
- Period of stay
- 13 days
- 0 times
- € 2.072,-
Groep 1€ 2.072,-
13 days stay
- 30 Oct 2017 up to and including 11 Nov 2017
Groep 2€ 2.072,-
13 days stay
- 13 Nov 2017 up to and including 25 Nov 2017
Groep 3€ 2.072,-
13 days stay
- 27 Nov 2017 up to and including 9 Dec 2017
Groep 4€ 2.072,-
13 days stay
- 11 Dec 2017 up to and including 23 Dec 2017